Zhitong Finance App News, Osecon (002755.SZ) announced that the first registered clinical phase III study of ASKC202 combined with liotinib, a class 1 innovative drug developed by Jiangsu Aosekang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was used to treat locally advanced or metastatic non-small cell lung cancer with EGFR-TKI treatment failure accompanied by MET amplification/overexpression.

Zhitongcaijing · 09/02/2025 09:25
Zhitong Finance App News, Osecon (002755.SZ) announced that the first registered clinical phase III study of ASKC202 combined with liotinib, a class 1 innovative drug developed by Jiangsu Aosekang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was used to treat locally advanced or metastatic non-small cell lung cancer with EGFR-TKI treatment failure accompanied by MET amplification/overexpression.